Zobrazeno 1 - 10
of 205
pro vyhledávání: '"WB Ershler"'
Autor:
SL Saraf, SU Abdullahi, AM Akinsete, FA Fasola, M Idowu, S Pennington, WB Ershler, MP Stagg, EA Lisbon, F Montealegre-Golcher
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S30- (2024)
Objectives: Osivelotor (previously GBT021601) is a next-generation sickle hemoglobin (HbS) polymerization inhibitor in development for sickle cell disease (SCD). Compared with the first-in-class HbS polymerization inhibitor voxelotor, osivelotor has
Externí odkaz:
https://doaj.org/article/f99675df14e04d7083ec2a0393b53830
Autor:
Mendez-Marti SR; Adult Sickle Cell Center, Inova Schar Cancer Institute, Inova Fairfax Medical Campus, Fairfax, VA, USA., Zik C; Adult Sickle Cell Center, Inova Schar Cancer Institute, Inova Fairfax Medical Campus, Fairfax, VA, USA., Alan S; Adult Sickle Cell Center, Inova Schar Cancer Institute, Inova Fairfax Medical Campus, Fairfax, VA, USA., Wang H; Biostatics, Bioinformatics and Biomathematics Department, Georgetown University, Washington, DC, USA., Ershler WB; Adult Sickle Cell Center, Inova Schar Cancer Institute, Inova Fairfax Medical Campus, Fairfax, VA, USA.
Publikováno v:
Journal of hematology [J Hematol] 2024 Jun; Vol. 13 (3), pp. 53-60. Date of Electronic Publication: 2024 Jun 28.
Autor:
Tuthill CW; LionHeart Consulting, St Helena, CA, USA. Electronic address: cyntut@gmail.com., Awad A; Clinical Research Consultants, LLC, Kansas City, MO, USA., Parrigon M; Clinical Research Consultants, LLC, Kansas City, MO, USA., Ershler WB; Inova Fairfax Hospital, Fairfax, VA, USA.
Publikováno v:
International immunopharmacology [Int Immunopharmacol] 2023 Apr; Vol. 117, pp. 109950. Date of Electronic Publication: 2023 Mar 02.
Autor:
Ershler WB; Department of Hematology, Inova Schar Cancer Institute, Fairfax, Virginia., De Castro LM; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania., Pakbaz Z; Division of Hematology/Oncology, UC Irvine Chao Family Cancer Center, Orange, California., Moynahan A; Policy Analysis Inc, Brookline, Massachusetts., Weycker D; Policy Analysis Inc, Brookline, Massachusetts., Delea TE; Policy Analysis Inc, Brookline, Massachusetts., Agodoa I; Global Blood Therapeutics, Inc., South San Francisco, California., Cong Z; Global Blood Therapeutics, Inc., South San Francisco, California.
Publikováno v:
Current therapeutic research, clinical and experimental [Curr Ther Res Clin Exp] 2023 Feb 23; Vol. 98, pp. 100696. Date of Electronic Publication: 2023 Feb 23 (Print Publication: 2023).
Autor:
Bade NA; Adult Sickle Center, Inova Schar Cancer Institute, Fairfax, Virginia, USA., Giri U; Adult Sickle Center, Inova Schar Cancer Institute, Fairfax, Virginia, USA., Wang H; Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Medical Center, Washington, District of Columbia, USA., Ershler WB; Adult Sickle Center, Inova Schar Cancer Institute, Fairfax, Virginia, USA.
Publikováno v:
Transfusion [Transfusion] 2022 Jul; Vol. 62 (7), pp. 1462-1464.
Autor:
Steimer M; Inova Schar Cancer Institute, Inova Health System, Falls Church, VA., Leabo J; Inova Schar Cancer Institute, Inova Health System, Falls Church, VA., Wang H; Georgetown University, Washington, DC., Heyer D; Inova Schar Cancer Institute, Inova Health System, Falls Church, VA., Addison N; Locus Health, Charlottesville, VA., Bowles N; Inova Schar Cancer Institute, Inova Health System, Falls Church, VA., Cannon TL; Inova Schar Cancer Institute, Inova Health System, Falls Church, VA., Cuevo R; Inova Schar Cancer Institute, Inova Health System, Falls Church, VA., Ershler WB; Inova Schar Cancer Institute, Inova Health System, Falls Church, VA., Shafer D; Inova Schar Cancer Institute, Inova Health System, Falls Church, VA., Jang S; Inova Schar Cancer Institute, Inova Health System, Falls Church, VA., Pennisi A; Inova Schar Cancer Institute, Inova Health System, Falls Church, VA., Al-Hussain A; Inova Schar Cancer Institute, Inova Health System, Falls Church, VA., Farrell K; Locus Health, Charlottesville, VA., Deeken JF; Inova Schar Cancer Institute, Inova Health System, Falls Church, VA.
Publikováno v:
JCO oncology practice [JCO Oncol Pract] 2021 Sep; Vol. 17 (9), pp. e1286-e1292. Date of Electronic Publication: 2021 Apr 01.
Autor:
Ershler WB; Benign Hematology Division, Inova Schar Cancer Institute, Fairfax, Virginia, USA., Holbrook ME; Benign Hematology Division, Inova Schar Cancer Institute, Fairfax, Virginia, USA.
Publikováno v:
Transfusion [Transfusion] 2020 Dec; Vol. 60 (12), pp. 3066-3067. Date of Electronic Publication: 2020 Sep 24.
Autor:
Ershler WB; Director, Benign Hematology Division, Inova Schar Cancer Institute, Inova Fairfax Medical Center, 3300 Gallows Road, Suite O-581, Falls Church, VA 22042, USA. Electronic address: william.ershler@inova.org.
Publikováno v:
Clinics in geriatric medicine [Clin Geriatr Med] 2019 Aug; Vol. 35 (3), pp. ix-x.
Autor:
Ershler WB; Division of Benign Hematology, Inova Schar Cancer Institute, Inova Fairfax Hospital, 3300 Gallows Road, Suite O-581, Falls Church, VA 22042, USA. Electronic address: william.ershler@inova.org.
Publikováno v:
Clinics in geriatric medicine [Clin Geriatr Med] 2019 Aug; Vol. 35 (3), pp. 295-305. Date of Electronic Publication: 2019 May 09.
A cell transportation solution that preserves live circulating tumor cells in patient blood samples.
Autor:
Stefansson S; HeMemics Biotechnologies Inc., 12111 Parklawn Drive, Rockville, MD, 20852, USA. stennistef@hememics.com., Adams DL; Creatv MicroTech, Inc., 1 Deer Park Dr., Monmouth Junction, NJ, 08852, USA., Ershler WB; Institute for Advanced Studies in Aging (IASIA), 6400 Arlington Blvd. Suite 940, Falls Church, VA, 22042, USA., Le H; Nauah Solutions, LLC., 1616 Anderson Rd., McLean, VA, 22101, USA., Ho DH; HeMemics Biotechnologies Inc., 12111 Parklawn Drive, Rockville, MD, 20852, USA.
Publikováno v:
BMC cancer [BMC Cancer] 2016 May 06; Vol. 16, pp. 300. Date of Electronic Publication: 2016 May 06.